We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-31.81%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$7.28M
AUM Growth
-$16.4M
Cap. Flow
-$13M
Cap. Flow %
-178.53%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
–
Closed
5

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
SLN
Silence Therapeutics
SLN
+$7.52M
2
CMPX icon
Compass Therapeutics
CMPX
+$4.22M
3
UTHR icon
United Therapeutics
UTHR
+$706K
4
GMED icon
Globus Medical
GMED
+$303K
5
TNDM icon
Tandem Diabetes Care
TNDM
+$254K

Sector Composition

Rank Sector Weight
1 Healthcare 97.05%
2 Miscellaneous 2.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZN icon
1
Surrozen
SRZN
$264M
$7.07M 97.05%
233,167
– –
SRZNW
2
DELISTED
Surrozen Inc Warrant
SRZNW
$215K 2.95%
1,165,832
– –
CMPX icon
3
Compass Therapeutics
CMPX
$432M
– –
-1,603,789
Closed -$4.22M
GMED icon
4
Globus Medical
GMED
$11.1B
– –
-5,405
Closed -$303K
SLN
5
Silence Therapeutics
SLN
$834M
– –
-634,270
Closed -$7.52M
TNDM icon
6
Tandem Diabetes Care
TNDM
$1.49B
– –
-4,294
Closed -$254K
UTHR icon
7
United Therapeutics
UTHR
$22.1B
– –
-2,998
Closed -$706K

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Consonance Capital Management held 7 positions worth $7.28M, down 69% from $23.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Consonance Capital Management withdrew a net $13M in Q3 2022, closing 5 positions. Its most notable exit was Silence Therapeutics, an estimated $7.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

  • Consonance Capital Management fully exited Silence Therapeutics in Q3 2022, selling an estimated $7.52M.
  • Consonance Capital Management's ten largest holdings make up 100% of its $7.28M portfolio in Q3 2022.
  • Consonance Capital Management opened 0 new positions and closed 5 in Q3 2022.
  • Consonance Capital Management's portfolio value fell 69% quarter-over-quarter to $7.28M.

Based on Consonance Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.